Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

van der Heijde Desiree; Song In-Ho; Pangan Aileen L.; Deodhar Atul; van den Bosch Filip; Maksymowych Walter P.; Kim Tae-Hwan; Kishimoto Mitsumasa; Everding Andrea; Sui Yunxia; Wang Xin; Chu Alvina D.; Sieper Joachim

首页> 外文期刊>The Lancet >Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

【24h】

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

机译：upadacitinib在有源强直性脊柱炎患者中的疗效和安全性（选择轴1）：多期，随机，双盲，安慰剂控制，第2/3阶段试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background The JAK pathway is a potential therapeutic target in ankylosing spondylitis. This study assessed the efficacy and safety of upadacitinib, a selective JAK1 inhibitor, in patients with ankylosing spondylitis.

机译：背景技术Jak途径是强直性脊柱炎的潜在治疗靶标。本研究评估了upadacitinib，一种选择性JAK1抑制剂，在强直性脊柱炎患者中的疗效和安全性。

著录项

来源
《The Lancet》 |2019年第10214期|共10页
作者
van der Heijde Desiree; Song In-Ho; Pangan Aileen L.; Deodhar Atul; van den Bosch Filip; Maksymowych Walter P.; Kim Tae-Hwan; Kishimoto Mitsumasa; Everding Andrea; Sui Yunxia; Wang Xin; Chu Alvina D.; Sieper Joachim;
展开▼
作者单位

Leiden Univ Dept Rheumatol Med Ctr NL-2300 RC Leiden Netherlands;

AbbVie Immunol Clin Dev &

Data &

Stat Sci N Chicago IL 60064 USA;

AbbVie Immunol Clin Dev &

Data &

Stat Sci N Chicago IL 60064 USA;

Oregon Hlth &

Sci Univ Div Arthrit &

Rheumat Dis Portland OR 97201 USA;

Univ Ghent VIB Ctr Inflammat Res Dept Internal Med &

Pediat Ghent Belgium;

Univ Alberta Dept Med Edmonton AB Canada;

Hanyang Univ Hosp Rheumat Dis Div Rheumatol Seoul South Korea;

Kyorin Univ Sch Med Dept Nephrol &

Rheumatol Tokyo Japan;

Hamburger Rheuma Forschungszentrum Hamburg Germany;

AbbVie Immunol Clin Dev &

Data &

Stat Sci N Chicago IL 60064 USA;

AbbVie Immunol Clin Dev &

Data &

Stat Sci N Chicago IL 60064 USA;

AbbVie Immunol Clin Dev &

Data &

Stat Sci N Chicago IL 60064 USA;

Charite Univ Med Berlin Dept Gastroenterol Infect Dis &

Rheumatol Berlin Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词
入库时间 2022-08-19 19:00:19

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial [J] . van der Heijde Desiree, Song In-Ho, Pangan Aileen L., The Lancet . 2019,第10214期

机译：upadacitinib在有源强直性脊柱炎患者中的疗效和安全性（选择轴1）：多期，随机，双盲，安慰剂控制，第2/3阶段试验
2. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial [J] . van der Heijde Desiree, Baraliakos Xenofon, Gensler Lianne S., The Lancet . 2018,第10162期

机译：菲尔替尼（一种有选择性的Janus激酶1抑制剂）的菌株和安全性，患有有源强直性脊柱胸腺炎（Tortuga）的患者：由随机，安慰剂控制，第2期试验结果
3. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial [J] . Burmester Gerd R., Kremer Joel M., Van den Bosch Filip, The Lancet . 2018,第10139期

机译：upadacitinib在类风湿性关节炎患者中的安全性和疗效和对常规合成疾病改性抗风湿药物的反应不足（选择 - 下一步）：随机，双盲，安慰剂控制第3期试验
4. A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL TO INVESTIGATE THE EFFICACY OF TIAMULIN IN THE CONTROL OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) AND PORCINE COLONIC SPIROCHAETOSIS (PCS) UNDER FIELD CONDITIONS [C] . J. Haugegaard, K. Moller, T.K. Jensen, Congress of the International Pig Veterinary Society . 2000

机译：一种双盲随机安慰剂对照临床试验，探讨硫霉素在野生植物中猪增殖肠病（PPE）和猪结肠螺旋肌肤症（PCS）的疗效
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Extended report: Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody ustekinumab in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3 multicentre double-blind placebo-controlled randomised PSUMMIT 2 trial [O] . Christopher Ritchlin, Proton Rahman, Arthur Kavanaugh, -1

机译：扩展报告：抗IL-12 / 23 p40单克隆抗体ustekinumab在活动性银屑病关节炎患者中的疗效和安全性尽管采用传统的非生物和生物抗肿瘤坏死因子疗法：6个月和1年的结果3期多中心双盲安慰剂对照随机PSUMMIT 2试验
7. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial [O] . Désirée van der Heijde, In-Ho Song, Aileen L Pangan, 2019

机译：upadacitinib在有源强直性脊柱炎患者中的疗效和安全性（选择轴1）：多期，随机，双盲，安慰剂控制，第2/3阶段试验

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

摘要

著录项

相似文献

相关主题

期刊订阅